

# Licensing Opportunity



University &  
University Hospital Lausanne

**The PACTT is proposing an exclusive or non-exclusive license for isolated DNA molecules having insulator or boundary properties and their uses.**

**Field:**

- Gene transfer vectors using genetic isolators.

**Development Phase:**

- Further genotoxicity evaluation (in vivo).
- Address insulator activity in different cell types and in different types of viral vectors.
- Sequence optimization.
- Production of recombinant proteins at higher yields and with lower development cost.

**Patent Status:**

- International Patent Application PCT/EP2009/064023 filed on October 23, 2009 in the name of University of Lausanne with priorities of October 23, 2008 (US 61/193,035) and of February 17, 2009 (US 61/202, 229).

**Innovative aspects:**

- DNA molecules with insulator or boundary properties.

**Additional information is available upon request** (N° Ref. IDF 05/07)

**Contact:**

Technology Transfer Office  
University and University  
Hospital Lausanne  
21, Rue du Bugnon  
CH - 1011 Lausanne  
Switzerland  
tel: +41 21 314 59 72  
fax: +41 21 314 49 57  
pactt.info@chuv.ch  
<http://www.pactt.ch>

## *Gene Transfer Vectors With Insulator or Boundary Properties and Methods to Identify Them*

**Background**

Better gene transfer systems are needed for increasing the specificity, efficiency and safety of genes vectors used in gene therapy.

**Description of the invention**

The invention relates to new DNA molecules having insulator or boundary properties and their use for the construction of vectors allowing a controlled genetic expression. Another aspect of the invention concerns the treatment of patients diagnosed with a genetic disease by administering such new vectors.

**Proof of concept**

Identification of isolated DNA molecules having insulator or boundary properties.

**Application and competitive advantages**

- Genetic isolators increasing the efficiency and safety in the use of viral vector in genetic therapy.
- Preventing the activation of chromosomal genes by the viral enhancers without interfering with therapeutic effects.
- Limiting the number of clones to obtain an efficient producing cell line.
- Improving the production yield of cell lines.